查看文章

Aim: To assess and compare the efficacy and safety of liraglutide with those of glimepiride, both in combination with metformin for the treatment of type 2 diabetes in Asian population from China, South Korea and India.

Methods: A 16‐week, randomized, double‐blind, double‐dummy, four‐arm, active control trial was carried out. In total, 929 subjects with type 2 diabetes with a mean (±s.d.) age of 53.3 ± 9.5 years, HbA_1c of 8.6 ± 1.0% and body weight of 68.1 ± 11.7 kg were randomized (liraglutide 0.6, 1.2 or 1.8 mg once daily or glimepiride 4 mg once daily all in combination with metformin: 1 : 1 : 1 : 1). One subject withdrew immediately after randomization and before exposure.

Results: HbA_1c was significantly reduced in all groups compared with baseline. Treatment with liraglutide 1.2 and 1.8 mg was non‐inferior to glimepiride (mean HbA_1c reduction: 1.36% points, 1.45% points and 1.39% points, respectively …